Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

2019 
Patients with moderate to severe haemophilia A are at a higher risk of developing FVIII inhibitors that require the use of more costly and less effective treatments. The objective of this study was...
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    16
    References
    2
    Citations
    NaN
    KQI
    []